Medimaps Group Launches MDR-Cleared TBS Osteo Advanced Software in Europe to Enhance Osteoporosis Detection and Management

Medimaps Group S.A., a global leader in AI-driven bone microarchitecture imaging solutions, has unveiled its next-generation TBS Osteo Advanced software in Europe, following its successful launch in the United States last month. The software, now MDR-cleared, is designed to enhance osteoporosis detection and bone health management, aligning with the company's goal of improving patient outcomes worldwide. TBS Osteo Advanced offers several significant advancements over its predecessor. It includes refined corrections for soft tissue thickness anterior to the lumbar spine, making the assessment more inclusive for patients with various body types. Additionally, the software introduces centralized system management capabilities, enabling healthcare providers to manage TBS assessments across multiple DXA systems and locations, thus streamlining clinical processes and ensuring consistent patient care. The software's user-friendly subscription model allows customers to access regular updates, new features, and support services. Existing TBS Osteo users can easily upgrade to the next-generation version to benefit from the enhanced functionalities. This flexible approach ensures that healthcare organizations remain at the forefront of osteoporosis care, adapting to the latest innovations and best practices. Univ. Prof. Dr. Didier Hans, CEO and Co-founder of Medimaps Group, emphasized the clinical benefits of TBS Osteo Advanced. "This software has been developed with busy radiology professionals in mind, aiming to maximize clinical output with minimal logistical efforts. It integrates seamlessly into existing workflows and provides comprehensive reports combining bone mineral density (BMD) and clinical factors within seconds, significantly enhancing diagnostic accuracy and treatment planning." Since its initial launch in 2012, TBS Osteo has been adopted globally by numerous top hospitals. The software is supported by over 1,400 peer-reviewed publications and is endorsed by more than 30 national and international osteoporosis assessment and management guidelines. TBS Osteo has become a gold standard in osteoporosis care, particularly in the U.S. Osteoporosis affects millions, particularly those aged 50 and over. The International Osteoporosis Foundation estimates that approximately 32 million Europeans in this age group have osteoporosis, with the annual number of osteoporotic fractures projected to increase from 4.33 million in 2019 to 5.34 million by 2034—an additional 1 million fractures annually. Despite effective treatments, only about 1 in 5 patients receive a proper diagnosis or therapy after experiencing an osteoporotic fracture. The introduction of TBS Osteo Advanced in Europe addresses these challenges by providing a more precise and efficient tool for osteoporosis assessment. By integrating advanced AI and improved imaging techniques, the software can help healthcare providers detect and monitor osteoporosis more effectively, ultimately reducing the socio-economic burden of osteoporotic fractures. Industry experts view this launch as a significant step forward in osteoporosis care. The ability to assess bone microarchitecture accurately and quickly, combined with centralized management and seamless integration, makes TBS Osteo Advanced a valuable addition to any healthcare provider's toolkit. The endorsement by leading academic and clinical bodies further solidifies its position as a gold-standard technology in the field. Medimaps Group, headquartered in Geneva, Switzerland, has a strong presence in the U.S. and France. The company's commitment to innovation and collaboration with world-class academics, clinicians, and industry partners positions it as a leader in advanced bone health management. Medimaps continues to develop cutting-edge imaging applications backed by robust clinical evidence, aiming to enhance the diagnosis and treatment of musculoskeletal conditions globally. For more information, visit www.medimaps.ai. This launch marks a crucial advancement in the field of osteoporosis management, leveraging AI and advanced imaging to provide more accurate and efficient assessments. The subscription model and upgrade options ensure that healthcare organizations can stay updated with the latest technological developments, enhancing their ability to diagnose and treat this prevalent condition. Medimaps Group’s focus on clinical relevance and ease of use underscores its dedication to improving patient care and reducing the economic impact of osteoporosis on healthcare systems.